[0008a] In one aspect of the present disclosure, there is provided a compound represented by:



wherein

Y is $S(O)_y$, wherein y is 2;

R^Z is H;

$R^{m'}$ and R^m are each H;

R^{22} is selected from the group consisting of X^2-phenyl, optionally substituted by one, or two substituents represented by R^{63}, phenyl optionally substituted by one, or two substituents represented by R^{63}, 5-6 membered monocyclic heteroaryl substituted by one, or two substituents represented by R^{63}, and 9-10 membered bicyclic heteroaryl optionally substituted by one, or two substituents represented by R^{63};

R' is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;

R'' is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, –C(O)-methyl and –C(O)-ethyl, or R' and R'' taken together with the nitrogen to which they are attached may form a 4-6 membered heterocycle;

each of moieties R^4, R^5, R^6, R^7, R^8, R^9, and R^{10} is independently selected for each occurrence from the group consisting of hydrogen, C_{1-6}alkyl, C_{2-6}alkynyl, C_{2-6}alkenyl, halogen, hydroxyl, nitro, cyano, and NR'R'';

R^{63} is selected independently at each occurrence from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C_{1-6}alkyl, -C(O)-O-C_{1-6}alkyl, heterocycle optionally substituted by halogen or NR'R', -C(O)-NR'R'', -C (=NH)-NR'R'', heteroaryl, phenyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, NR'R'', -C(O)-C_{1-6}alkyl,

-C(O)-C_{1-6}alkoxy, C_{3-6}cycloalkyl, -$S(O)_w$-C_{1-6}alkyl (where w is 0, 1 or 2), -$S(O)_w$-NR'R'' (where w is 0, 1 or 2), and -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2);

R^{69} is selected from the group consisting of H, halogen, hydroxyl, nitro, cyano, C_{1-6}alkyl, -C(O)-O-C_{1-6}alkyl, heterocycle optionally substituted by halogen or NR'R', -C(O)-NR'R'', -C (=NH)-NR'R'', heteroaryl, phenyl , C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, carboxy, NR'R'', -C(O)-C_{1-6}alkyl, -C(O)-C_{1-6}alkoxy, C_{3-6}cycloalkyl, -$S(O)_w$-C_{1-6}alkyl (where w is 0, 1 or 2), -$S(O)_w$-NR'R'' (where w is 0, 1 or 2), and -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2),

X^2 is selected from $S(O)_w$ (wherein w is 0), O, CH_2, or NR';

wherein for each occurrence, C_{1-6}alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C_{2-6}alkenyl, C_{2-6}alkynyl, NR'R'', -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2), and $S(O)_w$-NR'R''(where w is 0, 1 or 2); C_{1-6}alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C_{1-6}alkyl, NR'R'', -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0,1 or 2), and $S(O)_w$-NR'R'' (where w is 0, 1 or 2);
and pharmaceutically acceptable salts thereof.

[0008b] In another aspect of the present disclosure, there is provided a pharmaceutically acceptable composition comprising a compound disclosed herein, and a pharmaceutically acceptable excipient.

[0008c] In a further aspect of the present disclosure, there is provided a use of a compound disclosed herein in the manufacture of a medicament for treating a hepatitis B infection.

[0008d] In another aspect of the present disclosure, there is provided a compound disclosed herein for use in treating a hepatitis B infection.

WHAT IS CLAIMED IS:

1. A compound represented by:



wherein

Y is $S(O)_y$, wherein y is 2;

R^Z is H;

$R^{m'}$ and R^m are each H;

R^{22} is selected from the group consisting of X^2-phenyl, optionally substituted by one, or two substituents represented by R^{63}, phenyl optionally substituted by one, or two substituents represented by R^{63}, 5-6 membered monocyclic heteroaryl substituted by one, or two substituents represented by R^{63}, and 9-10 membered bicyclic heteroaryl optionally substituted by one, or two substituents represented by R^{63};

R' is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;

R'' is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, –C(O)-methyl and –C(O)-ethyl, or R' and R'' taken together with the nitrogen to which they are attached may form a 4-6 membered heterocycle;

each of moieties R^4, R^5, R^6, R^7, R^8, R^9, and R^{10} is independently selected for each occurrence from the group consisting of hydrogen, C_{1-6}alkyl, C_{2-6}alkynyl, C_{2-6}alkenyl, halogen, hydroxyl, nitro, cyano, and NR'R'';

R^{63} is selected independently at each occurrence from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C_{1-6}alkyl, -C(O)-O-C_{1-6}alkyl, heterocycle optionally substituted by halogen or NR'R', -C(O)-NR'R'', -C (=NH)-NR'R'', heteroaryl, phenyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, NR'R'', -C(O)-C_{1-6}alkyl, -C(O)-C_{1-6}alkoxy, C_{3-6}cycloalkyl, -$S(O)_w$-C_{1-6}alkyl (where w is 0, 1 or 2), -$S(O)_w$-NR'R'' (where w is 0, 1 or 2), and -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2);

R^{69} is selected from the group consisting of H, halogen, hydroxyl, nitro, cyano, C_{1-6}alkyl, -C(O)-O-C_{1-6}alkyl, heterocycle optionally substituted by halogen or NR'R', -C(O)-NR'R'', -C (=NH)-NR'R'', heteroaryl, phenyl , C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, carboxy, NR'R'', -C(O)-C_{1-6}alkyl, -C(O)-C_{1-6}alkoxy, C_{3-6}cycloalkyl, -$S(O)_w$-C_{1-6}alkyl (where w is 0, 1 or 2), -$S(O)_w$-NR'R'' (where w is 0, 1 or 2), and -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2),

X^2 is selected from $S(O)_w$ (wherein w is 0), O, CH_2, or NR';

wherein for each occurrence, C_{1-6}alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C_{2-6}alkenyl, C_{2-6}alkynyl, NR'R'', -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0, 1 or 2), and $S(O)_w$-NR'R''(where w is 0, 1 or 2); C_{1-6}alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C_{1-6}alkyl, NR'R'', -NR'-$S(O)_w$- C_{1-6}alkyl (where w is 0,1 or 2), and $S(O)_w$-NR'R'' (where w is 0, 1 or 2);
and pharmaceutically acceptable salts thereof.

2. The compound of claim 1, wherein R^{22} is X^2-phenyl optionally substituted by one, or two substituents represented by R^{63}, or phenyl optionally substituted by one, or two substituents represented by R^{63}.

3. The compound of claim 1 or 2, wherein R^{22} is 9-10 membered bicyclic heteroaryl optionally substituted by one, or two substituents represented by R^{63}.

4. The compound of any one of claims 1-3, wherein R^{22} is -X^2-phenyl optionally substituted by one, or two substituents represented by R^{63}.

5. The compound of any one of claims 1-4, wherein R^{22} is phenyl optionally substituted by one, or two substituents represented by R^{63}.

6. The compound of any one of claims 1-4, wherein R^{22} is a 5-6 membered monocyclic heteroaryl substituted by one, or two substituents represented by R^{63} or a 9-10 membered bicyclic heteroaryl optionally substituted by one, or two substituents represented by R^{63}.

7. The compound of any one of claims 1-6, represented by:


or


.

8. The compound of claim 7, wherein the compound is represented by:



.

9. The compound of claim 7, wherein the compound is represented by:


, wherein X^2 is selected from the group consisting of O, CH_2, and S.

10. The compound of any one of claims 1-3, wherein R^{22} is represented by a substituent selected from the group consisting of:


, 
, and 
.

11. The compound of any one of claims 1-10, wherein

R^{63} is selected independently at each occurrence from the group consisting of halogen, hydroxyl, nitro, cyano, C_{1-6}alkyl, C_{1-6}haloalkyl, -C_{1-6}alkyl-OH, -C(O)-O-C_{1-6}alkyl, -C(O)-NR'R'', -C (=NH)-NR'R'', C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, carboxy, NR'R'', -C(O)-C_{1-6}alkyl, -C(O)-C_{1-6}alkoxy, C_{3-6}cycloalkyl, -$S(O)_w$-C_{1-6}alkyl (where w is

0,1 or 2), -S(O)$_w$-NR'R'' (where w is 0, 1 or 2), and -NR'-S(O)$_w$- C_{1-6}alkyl (where w is 0, 1 or 2).

12. The compound of any one of claims 1-10, wherein

R^{63} is selected independently at each occurrence from the group consisting of halogen, hydroxyl, cyano, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{1-6}alkyl-OH, C_{1-6}alkyl-NR'R'', -O-C_{1-6}alkyl-NR'R'', -C_{1-6}alkyl-OH, -C(O)-NR'R'', C_{1-6}alkoxy, carboxy, and NR'R''.

13. A pharmaceutically acceptable composition comprising a compound of any one of claims 1-10, and a pharmaceutically acceptable excipient.

14. Use of a compound of any one of claims 1-10 in the manufacture of a medicament for treating a hepatitis B infection.

15. A compound of any one of claims 1-10 for use in treating a hepatitis B infection.